Android app on Google Play

Merck (MRK) Resubmits NDA for Ezetimibe, Atorvastatin Tabs

January 2, 2013 4:46 PM EST Send to a Friend
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of a New Drug Application (NDA) for ezetimibe and atorvastatin tablets, an investigational combination medicine. The updated NDA was deemed complete for review after Merck submitted additional data in response to the FDA’s Complete Response Letter issued last year. Merck expects the FDA’s review to be completed in the first half of 2013.




You May Also Be Interested In


Related Categories

Corporate News, FDA

Add Your Comment